• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks With Whale Alerts In Today's Session

    6/3/24 1:35:22 PM ET
    $BIIB
    $COR
    $CORT
    $GPCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Other Pharmaceuticals
    Health Care
    Get the next $BIIB alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels.

    Here's the list of options activity happening in today's session:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    PHR PUT TRADE NEUTRAL 06/21/24 $20.00 $570.0K 3.2K 3.1K
    LLY CALL SWEEP BEARISH 06/07/24 $850.00 $87.7K 386 1.2K
    CORT PUT SWEEP BEARISH 06/21/24 $30.00 $101.6K 1.4K 660
    GPCR PUT TRADE NEUTRAL 12/19/25 $50.00 $86.6K 0 571
    HIMS CALL SWEEP BULLISH 01/17/25 $20.00 $42.9K 12.6K 436
    NVAX CALL TRADE BULLISH 01/17/25 $20.00 $116.6K 4.2K 418
    COR PUT SWEEP BEARISH 06/21/24 $230.00 $61.2K 134 301
    BIIB CALL SWEEP BULLISH 06/14/24 $230.00 $26.4K 61 157
    VKTX CALL TRADE BULLISH 06/21/24 $60.00 $26.0K 666 121
    HCA PUT SWEEP BULLISH 06/20/25 $330.00 $27.4K 12 78

    Explanation

    These bullet-by-bullet explanations have been constructed using the accompanying table.

    • For PHR (NYSE:PHR), we notice a put option trade that happens to be neutral, expiring in 18 day(s) on June 21, 2024. This event was a transfer of 3000 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $570.0K, with a price of $190.0 per contract. There were 3204 open contracts at this strike prior to today, and today 3134 contract(s) were bought and sold.

    • For LLY (NYSE:LLY), we notice a call option sweep that happens to be bearish, expiring in 4 day(s) on June 7, 2024. This event was a transfer of 283 contract(s) at a $850.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $87.7K, with a price of $310.0 per contract. There were 386 open contracts at this strike prior to today, and today 1278 contract(s) were bought and sold.

    • Regarding CORT (NASDAQ:CORT), we observe a put option sweep with bearish sentiment. It expires in 18 day(s) on June 21, 2024. Parties traded 654 contract(s) at a $30.00 strike. This particular put needed to be split into 28 different trades to become filled. The total cost received by the writing party (or parties) was $101.6K, with a price of $160.0 per contract. There were 1416 open contracts at this strike prior to today, and today 660 contract(s) were bought and sold.

    • Regarding GPCR (NASDAQ:GPCR), we observe a put option trade with neutral sentiment. It expires in 564 day(s) on December 19, 2025. Parties traded 85 contract(s) at a $50.00 strike. The total cost received by the writing party (or parties) was $86.6K, with a price of $1020.0 per contract. There were 0 open contracts at this strike prior to today, and today 571 contract(s) were bought and sold.

    • For HIMS (NYSE:HIMS), we notice a call option sweep that happens to be bullish, expiring in 228 day(s) on January 17, 2025. This event was a transfer of 90 contract(s) at a $20.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $42.9K, with a price of $478.0 per contract. There were 12652 open contracts at this strike prior to today, and today 436 contract(s) were bought and sold.

    • Regarding NVAX (NASDAQ:NVAX), we observe a call option trade with bullish sentiment. It expires in 228 day(s) on January 17, 2025. Parties traded 299 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $116.6K, with a price of $390.0 per contract. There were 4211 open contracts at this strike prior to today, and today 418 contract(s) were bought and sold.

    • Regarding COR (NYSE:COR), we observe a put option sweep with bearish sentiment. It expires in 18 day(s) on June 21, 2024. Parties traded 153 contract(s) at a $230.00 strike. This particular put needed to be split into 26 different trades to become filled. The total cost received by the writing party (or parties) was $61.2K, with a price of $400.0 per contract. There were 134 open contracts at this strike prior to today, and today 301 contract(s) were bought and sold.

    • Regarding BIIB (NASDAQ:BIIB), we observe a call option sweep with bullish sentiment. It expires in 11 day(s) on June 14, 2024. Parties traded 44 contract(s) at a $230.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $26.4K, with a price of $600.0 per contract. There were 61 open contracts at this strike prior to today, and today 157 contract(s) were bought and sold.

    • For VKTX (NASDAQ:VKTX), we notice a call option trade that happens to be bullish, expiring in 18 day(s) on June 21, 2024. This event was a transfer of 50 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $26.0K, with a price of $520.0 per contract. There were 666 open contracts at this strike prior to today, and today 121 contract(s) were bought and sold.

    • For HCA (NYSE:HCA), we notice a put option sweep that happens to be bullish, expiring in 382 day(s) on June 20, 2025. This event was a transfer of 9 contract(s) at a $330.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $27.4K, with a price of $3050.0 per contract. There were 12 open contracts at this strike prior to today, and today 78 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more news on unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BIIB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIIB
    $COR
    $CORT
    $GPCR

    CompanyDatePrice TargetRatingAnalyst
    Eli Lilly and Company
    $LLY
    3/17/2026$850.00Hold → Reduce
    HSBC Securities
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$24.00Sell → Neutral
    Citigroup
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$23.00Underperform → Neutral
    BofA Securities
    Hims & Hers Health Inc.
    $HIMS
    3/9/2026$30.00Hold → Buy
    Needham
    Eli Lilly and Company
    $LLY
    2/25/2026$1250.00Outperform
    RBC Capital Mkts
    Hims & Hers Health Inc.
    $HIMS
    2/24/2026Buy → Neutral
    BTIG Research
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    Biogen Inc.
    $BIIB
    2/20/2026$185.00Equal Weight
    Barclays
    More analyst ratings

    $BIIB
    $COR
    $CORT
    $GPCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Eli Lilly downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Eli Lilly from Hold to Reduce and set a new price target of $850.00

    3/17/26 7:55:56 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hims & Hers Health upgraded by Citigroup with a new price target

    Citigroup upgraded Hims & Hers Health from Sell to Neutral and set a new price target of $24.00

    3/10/26 8:37:35 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health upgraded by BofA Securities with a new price target

    BofA Securities upgraded Hims & Hers Health from Underperform to Neutral and set a new price target of $23.00

    3/10/26 8:37:14 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $BIIB
    $COR
    $CORT
    $GPCR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form

    9/16/24 6:52:10 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)

    9/16/24 6:24:32 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BIIB
    $COR
    $CORT
    $GPCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

    Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE)Litifilimab was recently granted Breakthrough Therapy Designation by the FDA for CLE; AMETHYST Part A results supported the designationCLE is a serious autoimmune disease that impacts the daily lives of patients and can lead to permanent scarring and disfigurement when left untreated, and has no targeted treatment option CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced upcoming scientific presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place March 27-31. Late-breaki

    3/19/26 7:30:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes

    For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1Participants taking retatrutide 12 mg lost an average of 36.6 lbs (16.8%) No weight loss plateau was observed with retatrutide, with participants continuing their weight loss trajectory through 40 weeksINDIANAPOLIS, March 19, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced positive topline results from TRANSCEND-T2D-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, as an adjunct to diet and exercise. The trial enrolled adults diagn

    3/19/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cencora Announces Financial Leadership Transition

    Cencora reaffirms fiscal 2026 financial guidance Cencora, Inc. (NYSE:COR) today announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer effective June 30, 2026. Cencora has engaged an executive search firm to identify and evaluate potential successors from internal and external candidates. Mr. Cleary will assist in the search process and will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Mr. Cleary, 62, has served as Cencora's CFO since November 2018. He joined the Company in February 2015, following its acquisition of MWI Veterinary Supply, where he had served as Chief Executive Officer for over a de

    3/17/26 8:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $BIIB
    $COR
    $CORT
    $GPCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Becklund Irene

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    3/18/26 4:17:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Chi Michael

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    3/18/26 4:17:34 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Boughton Soleil

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    3/18/26 4:17:40 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $BIIB
    $COR
    $CORT
    $GPCR
    SEC Filings

    View All

    Cencora Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cencora, Inc. (0001140859) (Filer)

    3/17/26 8:45:16 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Phreesia Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Phreesia, Inc. (0001412408) (Filer)

    3/16/26 4:04:01 PM ET
    $PHR
    Real Estate

    Structure Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Structure Therapeutics Inc. (0001888886) (Filer)

    3/16/26 8:01:08 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIIB
    $COR
    $CORT
    $GPCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Head of Pharm Ops and Tech Murphy Nicole bought $585 worth of shares (3 units at $195.03), increasing direct ownership by 0.02% to 19,611 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    2/17/26 8:16:40 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIIB
    $COR
    $CORT
    $GPCR
    Financials

    Live finance-specific insights

    View All

    Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

    Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral GLP-1RAs and comparable efficacy to injectable GLP1-RAs Continued weight loss up to 16.2% (40.5 lbs) observed with 120 mg dose in the ACCESS Open Label Extension (OLE) study at 56 weeks, with no evidence of weight loss plateau Updated interim data from ACCESS OLE and Body Composition studies continue to support improved tolerability and low (2.0 – 3.4%) study drug discontinuations due to adverse events with the lower 2.5 mg starting dose End-of-Phase 2 meeting with FDA scheduled in the second

    3/16/26 7:00:00 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areasMultiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for the full year 2025Continued advancement of early-stage pipeline with the intention to enter the clinic as early as 2027Year end 2025 Cash of $751 million Novavax exceeded its full year 2025 R&

    2/26/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

    2025 revenue of $761.4 million Full year 2026 revenue guidance of $900 – $1,000 million 2025 net income of $99.7 million Cash and investments of $532.4 million at December 31, 2025 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2025. Financial Results "In 2025, our Cushing's syndrome business experienced a surge in demand due to growing recognition among physicians of hypercortisolism's true pr

    2/24/26 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIIB
    $COR
    $CORT
    $GPCR
    Leadership Updates

    Live Leadership Updates

    View All

    Cencora Announces Financial Leadership Transition

    Cencora reaffirms fiscal 2026 financial guidance Cencora, Inc. (NYSE:COR) today announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer effective June 30, 2026. Cencora has engaged an executive search firm to identify and evaluate potential successors from internal and external candidates. Mr. Cleary will assist in the search process and will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Mr. Cleary, 62, has served as Cencora's CFO since November 2018. He joined the Company in February 2015, following its acquisition of MWI Veterinary Supply, where he had served as Chief Executive Officer for over a de

    3/17/26 8:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Hims & Hers Names Kathryn Beiser as Chief Communications Officer

    The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world's leading consumer health platform in its next phase of growth Hims & Hers Health, Inc. (NYSE:HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company's expansive vision for the

    3/10/26 8:08:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

    Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company's ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structu

    2/19/26 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $BIIB
    $COR
    $CORT
    $GPCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

    SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

    11/14/24 5:46:12 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/14/24 4:30:54 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cencora Inc.

    SC 13G/A - Cencora, Inc. (0001140859) (Subject)

    11/14/24 1:22:34 PM ET
    $COR
    Other Pharmaceuticals
    Health Care